婴幼儿血管瘤药物治疗概述

中国口腔颌面外科杂志 ›› 2014, Vol. 12 ›› Issue (1): 1-6.

• 述评 • 下一篇

婴幼儿血管瘤药物治疗概述

郑家伟¹, 马坤宁², 张凌¹

1.上海交通大学医学院附属第九人民医院·口腔医学院口腔颌面外科,上海 200011; 2.滨州医学院口腔医学院2011级,山东烟台 264003

出版日期:2014-02-10 发布日期:2014-02-10
通讯作者: 郑家伟,Tel: 021- 23271063, Fax: 021- 63121780, E-mail:zhjw@omschina.org.cn
作者简介:郑家伟,男,医学博士,教授,博士(后)研究生导师。现任上海交通大学口腔医学院副院长,兼任国际脉管疾病研究学会(ISSVA)委员,中华口腔医学会口腔颌面外科专业委员会委员、脉管疾病学组副组长,口腔医学教育专业委员会副主任委员,《上海口腔医学》、《中国口腔颌面外科杂志》常务副主编,《Chinese J Med,CMJ》、《J Oral Maxillofac Surg, JOMS》、《Head Neck Oncology,HNO》、《中华医学教育探索杂志》等多本专业杂志编委。承担国家自然科学基金课题4项,主编著作4部(英文1部),参编著作23部(英文2部)。发表论文277篇,其中被SCI收录63篇,教学论文34篇(SCI收录6篇)。参与制定《中国口腔医学本科教育标准》、《口腔各科临床实习标准》,领衔制订6部头颈部血管瘤和脉管畸形诊治指南,其中4部在国际杂志发表,获得了广泛认可。
基金资助:
国家自然科学基金(81271163)

Overview of current pharmacotherapy for infantile hemangiomas

ZHENG Jia-wei¹, MA Kun-ning², ZHANG Ling¹

1. Department of Oral and Maxillofacial Surgery, Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine. Shanghai 200011; 2. Grade 2011, College of Stomatology, Binzhou Medical College. Yantai 264003, Shandong Province, China

Online:2014-02-10 Published:2014-02-10
Supported by:
Supported by National Natural Science Foundation of China (81271163).

摘要/Abstract

摘要： 婴幼儿血管瘤是儿童期最常见的良性肿瘤,往往对患儿的生长发育、外观和心理造成影响。传统的治疗方法包括药物、激光和手术3大手段,以药物治疗为主。常用的药物有糖皮质激素、β受体阻滞剂、平阳霉素、α干扰素、咪喹莫特等,对危及生命的重症患者,也可采用长春新碱等化疗药物治疗。本文简述了各种药物,尤其是β受体阻滞剂的特性及在婴幼儿血管瘤治疗中的应用。

关键词: 婴幼儿血管瘤, 药物治疗, 受体阻滞剂

Abstract: Infantile hemangiomas (IH) are the most common tumors of infancy and childhood. 60% of them are localized in the head and neck region. They may impinge on vital structures, ulcerate, bleed, cause high-output cardiac failure or significant disfigurement if left untreated. The traditional treatment methods include drug therapy, laser therapy and surgery, with drug therapy being the mainstay of treatment. The medications most commonly used to treat IH are corticosteroids, beta-adrenergic blocker, pingyangmycin, interferon alfa, imiquimod, and etc. For function- and life-threatening infantile hemangioma, some anti-cancer agents like vincristine may be used as an effective alternative option. This succinct review summarized current pharmacotherapeutic therpy of IH, especially the properties and effectiveness of various beta-adrenergic antagonists in the management of IH.

Key words: Infantile hemangioma, Drug therapy, beta-adrenergic blocker

郑家伟, 马坤宁, 张凌. 婴幼儿血管瘤药物治疗概述[J]. 中国口腔颌面外科杂志, 2014, 12(1): 1-6.

ZHENG Jia-wei, MA Kun-ning, ZHANG Ling. Overview of current pharmacotherapy for infantile hemangiomas[J]. China J Oral Maxillofac Surg, 2014, 12(1): 1-6.

参考文献

[1] Shah S, Frieden IJ. Treatment of infantile hemangiomas with Beta-blockers: a review[J]. Skin Therapy Lett, 2013,18(6):5-7.
[2] 郑家伟.婴幼儿血管瘤“等待观察”的治疗策略应予改变[J].中国口腔颌面外科杂志,2012,10(2):163-164.
[3] Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy[J]. N Engl J Med, 2008,358(24):2649-2651.
[4] Zimmermann AP, Wiegand S, Werner JA, et al. Propranolol therapy for infantile haemangiomas: review of the literature[J]. Int J Pediatr Otorhinolaryngol, 2010,74(4):338-342.
[5] Raphaël MF, de Graaf M, Breugem CC, et al. Atenolol: a promising alternative to propranolol for the treatment of hemangiomas[J]. J Am Acad Dermatol, 2011,65(2):420-421.
[6] Vedin A, Wilhelmsson C, BjÖrntorp P. Induction of diabetes and oral glucose tolerance tests during and after chronic beta-blockade[J]. Acta Med Scand Suppl, 1975,575:37-40.
[7] Eichhorn EJ. Effects of bucindolol in heart failure[J]. Am J Cardiol, 1993,71(9):65C-70C.
[8] Takase B, Hikita H, Uehata A, et al. Effect of carteolol on silent myocardial ischemia, variability in heart rate, and the pain-modulating system[J]. Am Heart J, 1997,134(5 Pt 1):945-954.
[9] Production Information: COREg (R) oral tablets, carvedilol oral tablets[Z]. GlaxosmithKline, Research Triangle Park, NC, 2011.
[10] Brogden RN, Heel RC, Speight TM, et al. Labetalol: a review of its pharmacology and therapeutic use in hypertension[J]. Drugs, 1978,15(4):251-270.
[11] Pope E, Chakkittakandiyil A, Lara-Corrales I, et al.Expanding the therapeutic repertoire of infantile haemangiomas: cohort-blinded study of oral nadolol compared with propranolol[J]. Br J Dermatol, 2013,168(1):222-224.
[12] McDevitt DG. Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs[J]. Eur Heart J,1987, Suppl M:9-14.
[13] Production information: levatol (R) oral tablet, penbutolol sulfate oral tablets[Z]. Schwarz Pharma, LLC(per FDA), Smyrna, GA, 2010.
[14] Isaac MT. Review: combining pindolol with an SSRI improves early outcomes in people with depression[J]. Evid Based Ment Health, 2004,7(4):107.
[15] Lynch M, Lenane P, O'Donnell BF. Propranolol for the treatment of infantile haemangiomas: our experience with 44 patients[J]. Clin Exp Dermatol, 2013,Dec 2.
[16] Saul JP, Schaffer MS, Karpawich PP, et al. Single-dose pharmacokinetics of sotalol in a pediatric population with supraventricular and/or ventricular tachyarrhythmia[J]. J Clin Pharmacol, 2001,41(1):35-43.
[17] Oranje AP, Janmohamed SR, Madern GC, et al.Treatment of small superficial haemangioma with timolol 0.5% ophthalmic solution:a series of 20 cases[J].Dermatology,2011,223(4):330-334.
[18] Fuchsmann C, Quintal MC, Giguere C, et al. Propranolol as first-line treatment of head and neck hemangiomas[J]. Arch Otolaryngol Head Neck Surg, 2011,137(5):471-478.
[19] de Graaf M, Raphael MF, Breugem CC, et al.Treatment of infantile haemangiomas with atenolol: Comparison with a historical propranolol group[J]. J Plast Reconstr Aesthet Surg, 2013,66(12):
[20] Production information: KERLONE (R) oral tablets, betaxolol hydrochloride oral tablets[Z]. Sanofi Synthelabo Inc., New York, NY, 2003.
[21] Production information: bisoprolol fumarate oral tablet[Z]. Teva Pharmaceuticals, Sellersvills, PA, 2003
[22] Production information: esmolol hydrochloride IV injection, esmolol hydrochloride IV injection[Z]. APP Pharmaceuticals, LLC, Schaumburg, IL, 2008.
[23] Greenberger S, Boscolo E, Adini I, et al. Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells[J]. N Engl J Med, 2010,362(11):1005-1013.
[24] Zhou Q, Yang XJ, Zheng JW, et al. Short-term high-dose oral prednisone on alternate days is safe and effective for treatment of infantile hemangiomas[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2010,109(2):166-167.
[25] Tan BH, Leadbitter PH, Aburn NH, et al. Steroid therapy for problematic proliferating haemangioma[J]. N Z Med J, 2011,124(1329):57-65.
[26] Izadpanah A, Izadpanah A, Kanevsky J, et al. Propranolol versus prednisone in the treatment of infantile hemangiomas: a retrospective comparative study[J]. Plast Reconstr Surg, 2013,131(3):601-613.
[27] Price CJ, Lattouf C, Baum B, et al. Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis[J]. Arch Dermatol, 2011,147(12):1371-1376.
[28] Martinez MI, Sanchez-Carpintero I, North PE, et al. Infantile hemangioma: clinical resolution with 5% imiquimod cream[J]. Arch Dermatol, 2002,138(7):881-884.
[29] Qiu Y, Ma G, Yang J, et al. Imiquimod 5% cream versus timolol 0.5% ophthalmic solution for treating superficial proliferating infantile haemangiomas: a retrospective study[J]. Clin Exp Dermatol, 2013,38(8):845-850.
[30] Chang E, Boyd A, Nelson CC, et al. Successful treatment of infantile hemangiomas with interferon-alpha-2b[J]. J Pediatr Hematol Oncol, 1997,19(3):237-244.
[31] Gottschling S, Schneider G, Meyer S, Reinhard H, et al. Two infants with life-threatening diffuse neonatal hemangiomatosis treated with cyclophosphamide[J].Pediatr Blood Cancer,2006,46(2):239-242.
[32] Fahrtash F, McCahon E, Arbuckle S. Successful treatment of kaposiform hemangioendothelioma and tufted angioma with vincristine[J]. J Pediatr Hematol Oncol, 2010,32(6):506-510.
[33] Fernandez-Pineda I, Lopez-Gutierrez JC, Chocarro G, et al. Long-term outcome of vincristine-aspirin-ticlopidine (VAT) therapy for vascular tumors associated with Kasabach-Merritt phenomenon[J]. Pediatr Blood Cancer, 2013,60(9):1478-1481.
[34] Fuchimoto Y, Morikawa N, Kuroda T, et al. Vincristine, actinomycin D, cyclophosphamide chemotherapy resolves Kasabach-Merritt syndrome resistant to conventional therapies[J]. Pediatr Int, 2012,54(2):285-287.
[35] Hou J, Wang M, Tang H, et al. Pingyangmycin sclerotherapy for infantile hemangiomas in oral and maxillofacial regions: an evaluation of 66 consecutive patients[J]. Int J Oral Maxillofac Surg, 2011,40(11):1246-1251.
[36] 郑家伟,赵怡芳.平阳霉素治疗脉管性疾病规范[J]. 中国口腔颌面外科杂志,2011,9(1):68-69.

婴幼儿血管瘤药物治疗概述

Overview of current pharmacotherapy for infantile hemangiomas

RichHTML

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李晓, 范新东, 郑家伟. 脉管异常的ISSVA分类概要及分子生物学研究进展[J]. 中国口腔颌面外科杂志, 2023, 21(3): 286-290.
[2]	郑家伟, 王绪凯, 秦中平, 范新东, 李凯, 杨耀武, 霍然, 刘少华, 赵吉宏, 汪小勇, 周德凯, 刘学键. 口服普萘洛尔治疗婴幼儿血管瘤中国专家共识（2022版）[J]. 中国口腔颌面外科杂志, 2022, 20(4): 313-319.
[3]	郑家伟, 赵泽亮, 陈启铭. 婴幼儿血管瘤循证治疗现状[J]. 中国口腔颌面外科杂志, 2022, 20(1): 7-14.
[4]	王杞章, 郑家伟. 口服普萘洛尔治疗婴幼儿增殖期血管瘤:英国儿科皮肤病学会共识及临床指南[J]. 中国口腔颌面外科杂志, 2020, 18(6): 548-552.
[5]	顾达, 霍然, 徐广琪, 毕见海, 李尚滨. 局部外用β受体阻滞剂治疗婴幼儿血管瘤的临床应用研究进展[J]. 中国口腔颌面外科杂志, 2020, 18(4): 375-380.
[6]	李红, 周昱川, 龚忠诚, 孙杨, 凌彬. 口服普萘洛尔联合外用盐酸倍他洛尔治疗8例眶周高风险婴幼儿血管瘤的疗效和安全性评价[J]. 中国口腔颌面外科杂志, 2020, 18(3): 264-268.
[7]	宋会新, 林春男, 王田友, 付兆臣. 普萘洛尔治疗婴幼儿血管瘤的作用机制研究进展[J]. 中国口腔颌面外科杂志, 2020, 18(2): 182-185.
[8]	刘学键, 刘志鹏, 武宜雷, 邰茂众. 平阳霉素新剂型瘤体内注射治疗婴幼儿血管瘤203例临床分析[J]. 中国口腔颌面外科杂志, 2019, 17(3): 247-250.
[9]	张凯驰, 徐大朋, 程沫沙, 王绪凯. 马来酸噻吗洛尔和普萘洛尔治疗婴幼儿表浅型血管瘤的疗效分析[J]. 中国口腔颌面外科杂志, 2017, 15(6): 529-533.
[10]	周昱川，凌彬，龚忠诚，许颖捷，陈青立. 外涂盐酸倍他洛尔滴眼液治疗7例表浅型婴幼儿血管瘤疗效观察[J]. 中国口腔颌面外科杂志, 2017, 15(5): 438-441.
[11]	程沫沙，张凯驰，王绪凯. 普萘洛尔治疗溃疡性婴幼儿血管瘤18例临床分析[J]. 中国口腔颌面外科杂志, 2017, 15(3): 264-267.
[12]	王菲楠, 范新东. 放射性核素治疗婴幼儿血管瘤的现状[J]. 中国口腔颌面外科杂志, 2016, 14(5): 471-474.
[13]	彭昊，周国瑜，赵建鑫，沈玲悦，马川. 组织块法建立婴幼儿血管瘤动物模型的实验研究[J]. 中国口腔颌面外科杂志, 2015, 13(6): 486-490.
[14]	王亚飞, 周权, 王忠强. 小剂量盐酸普萘洛尔口服治疗不同月龄婴幼儿血管瘤临床疗效观察[J]. 中国口腔颌面外科杂志, 2015, 13(1): 38-41.
[15]	王佳, 石静, 王绪凯. 0.5%马来酸噻吗洛尔溶液联合普萘洛尔治疗婴幼儿血管瘤的不良反应观察[J]. 中国口腔颌面外科杂志, 2014, 12(6): 539-542.